Offering End-to-End Solutions
Suzhou, China – WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has successfully completed the mock-up testing of the isolator filling line at its Suzhou Site, which is the Company’s first isolator filling line in China. This significant milestone marks the completion of the design stage and entry into the manufacturing stage of the filling line.
Aseptic filling is critical in vaccine production, and its speed and efficiency determine the production capacity of finished vaccines. The isolator filling line provides the Suzhou Site with an annual production capacity of 20 million at 2R. The line is capable to support fill & finish using 2R-50R vials. It accommodates the filling of vaccines in liquid formulation, lyophilized (freeze-dried) vaccines, and vaccines with suspension formulation.
The Suzhou Site is the first dedicated vaccine production facility owned independently by WuXi Vaccines in China. The completion of the isolator filling line is an important component of capacity building for WuXi Vaccines vaccine commercialization, as it enables the company to provide high-quality vaccines that meet and exceed customer needs.
“We are proud to have achieved this significant milestone in our vaccine production capabilities,” said Mr. Jian Dong, CEO of WuXi Vaccines. “Our team has worked tirelessly to complete the design stage and enter the manufacturing stage of the filling line in a remarkably short amount of time. This achievement is a testament to our commitment to delivering safe and effective vaccines to people worldwide.”
About WuXi Vaccines
WuXi Vaccines is a leading contract development and manufacturing organization (CDMO) that focuses on vaccine development and manufacturing. It provides world-class integrated development and manufacturing platforms to expedite partners’ vaccines to the clinical stage and the market, regardless of the vaccine modality (i.e., protein, virus, VLP, DNA, mRNA/RNA). With its technical expertise, broad regulatory knowledge, premium quality system, advanced CMC development capabilities, multiple production platforms (mammalian, microbial), and extensive GMP manufacturing capacities, WuXi Vaccines provides an end-to-end service – from vaccine discovery and development to large-scale commercial production and distribution. The company can enable any global partner to deliver critical vaccines anywhere in the world, making it an essential partner in protecting public health.
For more information, please visit https://wuxivaccines.com.